ConductScience.org, home

Paper528263

Terminology in the description of drug-radiation interactions.

Steel GG. Int J Radiat Oncol Biol Phys, 1979. Cited by 174 papers, by iCite.

Cite this record

ConductScience Library. Terminology in the description of drug-radiation interactions. Papers, record 528263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/528263

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Terminology in the description of drug-radiation interactions.
PubMed
Journal
Int J Radiat Oncol Biol Phys
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
174
iCite
Relative citation ratio, by iCite
5.59
iCite
Revised in PubMed
2019-07-08
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Steel GGG G

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Neoplasms, ExperimentalMajor topic
RadiotherapyMajor topic
Terminology as TopicMajor topic
Animals
Cell Survival
Cells, Cultured
Cricetinae
Dose-Response Relationship, Radiation
Mice
Radiation Injuries, Experimental
Radiation-Protective Agents
Radiation-Sensitizing Agents

Source PubMed

Download CSV of topics

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 174 citations.

PMIDTitleJournalYearIn PapersSource
41117982Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.Eur J Nucl Med Mol Imaging2026https://conductscience.org/library/papers/41117982PubMed
40583736Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.Thorac Cancer2025https://conductscience.org/library/papers/40583736PubMed
36760380Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review.Transl Cancer Res2023https://conductscience.org/library/papers/36760380PubMed
35976726The State of Preclinical Modeling for Early Phase Cancer Trials Using Molecularly Targeted Agents with Radiation.Radiat Res2022https://conductscience.org/library/papers/35976726PubMed
35716328Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer.Curr Treat Options Oncol2022https://conductscience.org/library/papers/35716328PubMed
32914000Applying Precision Oncology Principles in Radiation Oncology.JCO Precis Oncol2018https://conductscience.org/library/papers/32914000PubMed
32731592DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage.Cancers (Basel)2020https://conductscience.org/library/papers/32731592PubMed
32668592Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib.Cancers (Basel)2020https://conductscience.org/library/papers/32668592PubMed
32335187The Promise of Combining Radiation Therapy With Immunotherapy.Int J Radiat Oncol Biol Phys2020https://conductscience.org/library/papers/32335187PubMed
27043632Radioresistance of Brain Tumors.Cancers (Basel)2016https://conductscience.org/library/papers/27043632PubMed
26205191EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.Pharmacol Ther2015https://conductscience.org/library/papers/26205191PubMed
25113770Interaction of radiation therapy with molecular targeted agents.J Clin Oncol2014https://conductscience.org/library/papers/25113770PubMed
24944704Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells.Oncol Lett2014https://conductscience.org/library/papers/24944704PubMed
23393324Fenbendazole as a potential anticancer drug.Anticancer Res2013https://conductscience.org/library/papers/23393324PubMed
22862779Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.Radiat Res2012https://conductscience.org/library/papers/22862779PubMed
22111842Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.Int J Radiat Biol2012https://conductscience.org/library/papers/22111842PubMed
21140241Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.Med Oncol2012https://conductscience.org/library/papers/21140241PubMed
19884901Liver metastases from colorectal cancer: radioembolization with systemic therapy.Nat Rev Clin Oncol2009https://conductscience.org/library/papers/19884901PubMed
15642164Letrozole sensitizes breast cancer cells to ionizing radiation.Breast Cancer Res2005https://conductscience.org/library/papers/15642164PubMed
11714450Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.Jpn J Cancer Res2001https://conductscience.org/library/papers/11714450PubMed

See all 38 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/528263

GET https://conductscience.org/api/papers/v1/528263/cited_by?page=2